Prescription attached:-

đ§ LIPU MED â FULL CLINICAL CASE REVIEW
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§: āĻšāĻžāĻāĻā§āϰ āĻĒā§āϰā§āύ⧠Posterior Cruciate Ligament (PCL) āĻāĻāĻžāϤ, āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Tibial Plateau Fracture-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻāĻžāϤ-āĻĒāϰāĻŦāϰā§āϤ⧠āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻāĻŋāĻāĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏāĨ¤
Confidence: 0.76 â Provisional clinical interpretation
Website Publication Information
| Parameter | Information |
|---|---|
| Proposed TC Number | TC(1447) â Provisional |
| Department Code | (05) Orthopedics |
| Department Case No. | 188 â Proposed |
| Proposed DCS | DCS(05)-188 â Provisional internal identifier |
| Prescription | 1 |
| Investigation Report | 0 |
| Clinical Images | 1 prescription photograph |
| Original Prescription Date | Appears to be 12 September 2016; handwriting uncertain |
| Review Date | Wednesday, 28 October 2026 |
| Department | Orthopedics & Trauma Surgery |
| Original Physician | Lt. Col. Dr. Suman Kumar Sen |
| Hospital | MARKS Medical College & Hospital, Dhaka |
| Review Type | Retrospective clinical and pharmacological analysis |
Website verification: raiyyantahsan.com-āĻāϰ Orthopedics archive-āĻ ā§¨ā§ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āϏāϰā§āĻŦāĻļā§āώ āĻĻā§āĻļā§āϝāĻŽāĻžāύ Orthopedics case āĻāĻŋāϞ TC(1446), Department Case No. 187āĨ¤ āϏā§āĻ āϧāĻžāϰāĻžāĻŦāĻžāĻšāĻŋāĻāϤāĻžā§ Case No. 188 āĻĒā§āϰāϏā§āϤāĻžāĻŦ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Important: TC(1447) āϏāĻžāĻāĻā§āϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ global registry-āϤ⧠āĻ āύā§āϝ āĻŦāĻŋāĻāĻžāĻā§ āĻāϤāĻŋāĻŽāϧā§āϝ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž, āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤ āĻāĻāĻŋ āĻĒā§āϰāĻāĻžāĻļāύāĻžāϰ āĻāύā§āϝ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ, āύāĻŋāĻŦāύā§āϧāĻŋāϤ āĻŦāĻž āϏāĻāϰāĻā§āώāĻŋāϤ āύāĻŽā§āĻŦāϰ āύā§āĨ¤
Confidence: 0.90 for the observed Orthopedics sequence; 0.60 for global TC uniqueness.
đ§ PART 1 â ORIGINAL PRESCRIPTION ANALYSIS
1. Patient Information â āϰā§āĻā§āϰ āϤāĻĨā§āϝ
| Parameter | Prescription Finding | Confidence |
|---|---|---|
| Name â āύāĻžāĻŽ | Handwriting unclear; privacy-protected for publication | 0.55 |
| Age â āĻŦā§āϏ | Approximately 26 years, subject to verification | 0.65 |
| Sex â āϞāĻŋāĻā§āĻ | Male â āĻĒā§āϰā§āώ | 0.96 |
| Consultation Date â āϤāĻžāϰāĻŋāĻ | Possibly 12/09/2016 | 0.65 |
| Department â āĻŦāĻŋāĻāĻžāĻ | Orthopedics â āĻ āϰā§āĻĨā§āĻĒā§āĻĄāĻŋāĻāϏ | 0.99 |
| Clinical context â āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻžāϰāĻŖ | Previous knee injury and degenerative joint disorder | 0.88 |
āϰā§āĻā§āϰ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻĒāϰāĻŋāĻā§ āĻĒā§āϰāĻāĻžāĻļ āύāĻž āĻāϰ⧠Patient X āĻšāĻŋāϏā§āĻŦā§ Case Report āĻĒā§āϰāĻāĻžāĻļ āĻāϰāĻžāĻ āĻāĻĒāϝā§āĻā§āϤāĨ¤
2. C/C â Chief Complaints â āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
What the Doctor Documented
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞāĻžāĻĻāĻž āĻāϰ⧠Chief Complaints āĻŦāĻž āϰā§āĻā§āϰ āύāĻŋāĻā§āϰ āĻāĻžāώāĻžā§ āĻāĻĒāϏāϰā§āĻā§āϰ āĻŦāĻŋāĻŦāϰāĻŖ āϞā§āĻāĻž āύā§āĻāĨ¤
āϤāĻŦā§ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύā§āĻ āĻ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧāĻā§āϞ⧠āĻĨā§āĻā§ āĻāĻŋāĻā§ āĻāĻĒāϏāϰā§āĻ āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžā§āĨ¤
Possible Clinical Complaints â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
- Chronic Knee Pain â āĻĻā§āϰā§āĻāĻĻāĻŋāύā§āϰ āĻšāĻžāĻāĻā§āĻŦā§āϝāĻĨāĻžāĨ¤
Osteoarthritis āĻāĻŦāĻ āĻĒā§āϰā§āύ⧠āĻšāĻžāĻāĻā§āϰ āĻāĻāĻžāϤā§āϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤ āϤāĻŦā§ āĻŦā§āϝāĻĨāĻž āĻāϤāĻĻāĻŋāύā§āϰ āĻŦāĻž āĻāϤāĻāĻž āϤā§āĻŦā§āϰ, āϤāĻž āϞā§āĻāĻž āύā§āĻāĨ¤ - Possible Knee Instability â āĻšāĻžāĻāĻā§ āĻ
āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞ āĻšāĻā§āĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
PCL injury āĻĨāĻžāĻāϞ⧠āĻšāĻžāĻāĻā§ āĻĸāĻŋāϞ⧠āϞāĻžāĻāĻž āĻŦāĻž āĻšāĻžāĻāĻā§āϰ āĻāĻĒāϰ āĻāϰ āĻĻāĻŋāϞ⧠āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻ āύā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ - Possible Functional Limitation â āĻšāĻžāĻāĻā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āĻāĻāĻžāϤ āĻ Thigh Muscle Wasting āĻĨāĻžāĻāϞ⧠āĻšāĻžāĻāĻāĻž, āϏāĻŋāĻā§āĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻž āĻĻā§āϰā§āĻāĻā§āώāĻŖ āĻĻāĻžāĻā§āĻŋā§ā§ āĻĨāĻžāĻāϤ⧠āĻ āϏā§āĻŦāĻŋāϧāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical documentation warning: āĻāĻā§āϞ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĒāϏāϰā§āĻ, āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āύāĻŋāĻļā§āĻāĻŋāϤ C/C āύā§āĨ¤
Confidence: Knee pain 0.82 | Instability 0.65 | Functional limitation 0.60
3. I/H â Illness History â āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
Documented Information
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏāĻŽā§āĻāĻŦāϤ āϞā§āĻāĻž āϰā§ā§āĻā§:
Old PCL Injury â Posterior Cruciate Ligament-āĻāϰ āĻĒā§āϰā§āύ⧠āĻāĻāĻžāϤāĨ¤
āĻāĻāĻŋ āĻšāĻžāĻāĻā§āϰ āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāĻĻāĻžāύāĻāĻžāϰ⧠āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻāĻžāϤ āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰā§āĨ¤
Clinical Interpretation
PCL āĻšāĻžāĻāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻĻāĻŋāĻā§ Tibia-āĻāϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϏāϰ⧠āϝāĻžāĻā§āĻž āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻāϰā§āĨ¤
āĻĒā§āϰā§āύ⧠PCL injury-āĻāϰ āĻĢāϞ⧠āĻāĻŋāĻā§ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž, āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻĻā§āϰā§āĻŦāϞāϤāĻž āĻāĻŦāĻ āĻĒāϰāĻŦāϰā§āϤ⧠āϏāĻŽā§ā§ āĻā§ā§āύā§āĻā§āϰ āĻā§āώā§āĻāύāĻŋāϤ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Not documented: āĻāĻāĻžāϤā§āϰ āϤāĻžāϰāĻŋāĻ, āĻĻā§āϰā§āĻāĻāύāĻžāϰ āϧāϰāύ, āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠MRI, āĻ āĻĒāĻžāϰā§āĻļāύ, āĻĢāĻŋāĻāĻŋāĻāĻĨā§āϰāĻžāĻĒāĻŋ āĻ āĻĨāĻŦāĻž āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĢāϞāĻžāĻĢāϞāĨ¤
Confidence: 0.88 for historical PCL injury; 0.75 for its possible contribution to current joint pathology.
4. O/H â Obstetric / Occupational History â āĻĒā§āϰāϏā§āϤāĻŋ āĻ āĻĨāĻŦāĻž āĻĒā§āĻļāĻžāĻāϤ āĻāϤāĻŋāĻšāĻžāϏ
Obstetric History â āĻĒā§āϰāϏā§āϤāĻŋ āĻāϤāĻŋāĻšāĻžāϏ: āĻĒā§āϰā§āώ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Occupational History â āĻĒā§āĻļāĻžāĻāϤ āĻāϤāĻŋāĻšāĻžāϏ: āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
āĻĒā§āĻļāĻžāĻāϤ āĻāĻžāĻā§āϰ āϧāϰāύ āĻāĻžāύāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ āĻĻā§āϰā§āĻāĻā§āώāĻŖ āĻĻāĻžāĻā§āĻŋā§ā§ āĻĨāĻžāĻāĻž, āĻāĻžāϰ⧠āĻāĻŋāύāĻŋāϏ āĻŦāĻšāύ āĻāϰāĻž, āĻšāĻžāĻāĻā§ āĻāĻžāĻāĻ āĻāϰ⧠āĻāĻžāĻ āĻāϰāĻž āĻ āĻĨāĻŦāĻž āĻā§āϞāĻžāϧā§āϞāĻžā§ āĻ āĻāĻļāĻā§āϰāĻšāĻŖ āĻāϰāϞ⧠āĻšāĻžāĻāĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.99 that occupational history is not documented.
5. D/H â Drug History â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤāĻŋāĻšāĻžāϏ āύā§āĻāĨ¤
āĻŦāϰā§āϤāĻŽāĻžāύ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāĻžāϰāĻāĻŋ āĻāώā§āϧ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āϝāĻžā§:
- Ternilla 100 mg
- Maxpro MUPS 20 mg
- Ostocal DX
- Arthrosin TS
Important: Prescribed medication āĻāĻŦāĻ Past Drug History āĻāĻāĻ āĻŦāĻŋāώ⧠āύā§āĨ¤ āĻ āϤā§āϤ⧠āϰā§āĻā§ āĻā§āύ āĻāώā§āϧ āĻā§ā§ā§āĻā§āύ, āϤāĻž āĻāĻžāύāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Confidence: 0.96 for identified brands; 0.99 that past medication history is unavailable.
6. M/H â Menstrual History â āĻŽāĻžāϏāĻŋāĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
āϰā§āĻā§ Male āĻšāĻā§āĻžā§ Menstrual History āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Confidence: 0.99
7. O/G/E â On General Examination â āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
āύāĻŋāĻā§āϰ āϤāĻĨā§āϝāĻā§āϞ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋ:
| Examination | English Meaning | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ |
|---|---|---|
| BP | Blood Pressure | āϰāĻā§āϤāĻāĻžāĻĒ |
| Pulse | Heart Rate | āĻšā§āĻĻāϏā§āĻĒāύā§āĻĻāύ |
| Temperature | Body Temperature | āĻļāϰā§āϰā§āϰ āϤāĻžāĻĒāĻŽāĻžāϤā§āϰāĻž |
| BMI | Body Mass Index | āĻāĻā§āĻāϤāĻž āĻ āύā§āϝāĻžā§ā§ āĻāĻāύā§āϰ āϏā§āĻāĻ |
| Pallor | Clinical pallor | āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻžāϰ āĻŦāĻžāĻšā§āϝāĻŋāĻ āϞāĻā§āώāĻŖ |
| Edema | Swelling | āĻĢā§āϞāĻž |
| General appearance | Overall clinical condition | āϰā§āĻā§āϰ āϏāĻžāĻŽāĻā§āϰāĻŋāĻ āĻ āĻŦāϏā§āĻĨāĻž |
Assessment: General examination findings are not documented.
Confidence: 0.99
8. O/S/E â On Systemic Examination â āĻ āĻā§āĻāϤāύā§āϤā§āϰāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Musculoskeletal Examination-āĻāϰ āĻāĻŋāĻā§ āϤāĻĨā§āϝ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
A. Thigh Muscle Wasting â āĻāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻļā§āĻāĻŋā§ā§ āϝāĻžāĻā§āĻž
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύā§āĻā§ āϏāĻŽā§āĻāĻŦāϤ Thigh Wasting (+) āϞā§āĻāĻž āϰā§ā§āĻā§āĨ¤
Definition: Thigh Muscle Wasting āĻšāϞ⧠āĻāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻā§āϤāύ āĻāĻŽā§ āϝāĻžāĻā§āĻžāĨ¤
Possible causes:
- āĻĻā§āϰā§āĻāĻĻāĻŋāύ āĻšāĻžāĻāĻā§ āĻāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāĨ¤
- āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻŦā§āϝāĻĨāĻžāϰ āĻāĻžāϰāĻŖā§ Quadriceps inhibitionāĨ¤
- āĻĒā§āϰā§āύ⧠āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ āĻŦāĻž āĻā§ā§āύā§āĻā§āϰ āĻāĻāĻžāϤāĨ¤
- āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāĨ¤
Clinical significance: Thigh wasting āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ findingāĨ¤ āĻāĻāĻŋ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ functional impairment-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ, āϤāĻŦā§ āĻāĻāĻž PCL tear āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āύāĻžāĨ¤
Confidence: 0.80
B. PD Test Positive â Posterior Drawer Test āĻĒāĻāĻŋāĻāĻŋāĻ
āĻšāĻžāϤā§āϰ āϞā§āĻāĻžāĻāĻŋ PD Test +ve āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤
Posterior Drawer Test: āĻšāĻžāĻāĻā§ āĻĒā§āϰāĻžā§ ā§¯ā§Ļ āĻĄāĻŋāĻā§āϰāĻŋ āĻāĻžāĻāĻ āĻāϰ⧠Tibia āĻĒā§āĻāύā§āϰ āĻĻāĻŋāĻā§ āϏāϰ⧠āϝāĻžā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻž āĻšā§āĨ¤
Positive Test: āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻā§āϰ āϤā§āϞāύāĻžā§ Tibia āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻĒā§āĻāύ⧠āϏāϰ⧠āĻā§āϞ⧠PCL insufficiency āϏāύā§āĻĻā§āĻš āĻāϰāĻž āĻšā§āĨ¤
Clinical significance: Positive Posterior Drawer Test PCL injury-āĻāϰ āĻĒāĻā§āώ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ clinical evidenceāĨ¤
āϤāĻŦā§ āĻāĻŦāĻŋāϰ handwriting āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ āĻĒāϰā§āĻā§āώāĻžāĻāĻŋ āϏāϤā§āϝāĻŋāĻ Positive āĻāĻŋāϞ āĻāĻŋ āύāĻž āĻāĻŦāĻ āĻāϤāĻāĻž posterior laxity āĻāĻŋāϞ, āϤāĻž āĻĒā§āύāϰāĻžā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.76 for transcription; 0.93 for the clinical significance of a confirmed positive test.
C. Other Required Knee Examination
Documented āύā§, āĻāĻŋāύā§āϤ⧠āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻĒā§āϰā§ā§āĻāύ:
- Knee ROM â āĻšāĻžāĻāĻā§ āĻāϤāĻāĻž āĻāĻžāĻāĻ āĻ āϏā§āĻāĻž āĻāϰāĻž āϝāĻžā§āĨ¤
- Joint-line tenderness â āĻā§ā§āύā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϏā§āĻĨāĻžāύ⧠āĻāĻžāĻĒ āĻĻāĻŋāϞ⧠āĻŦā§āϝāĻĨāĻžāĨ¤
- Effusion â āĻšāĻžāĻāĻā§āϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϤāϰāϞāĨ¤
- Posterior sag sign â Tibia āĻĒā§āĻāύ⧠āĻŦāϏ⧠āϝāĻžāĻā§āĻžāϰ āϞāĻā§āώāĻŖāĨ¤
- Quadriceps strength â āĻāϰā§āϰ āϏāĻžāĻŽāύā§āϰ āĻĒā§āĻļāĻŋāϰ āĻļāĻā§āϤāĻŋāĨ¤
- Varus/valgus stability â āĻšāĻžāĻāĻā§āϰ āĻĒāĻžāĻļā§āϰ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāĨ¤
- Neurovascular examination â āĻĒāĻžā§ā§āϰ āϰāĻā§āϤāĻĒā§āϰāĻŦāĻžāĻš āĻ āϏā§āύāĻžā§ā§āϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāĨ¤
Confidence: 0.95 for the recommended assessment components.
đ§ PART 2 â DOCTOR’S DIAGNOSIS
9. Doctor’s Written Dx â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻŦāĻžāĻŽ āĻ āĻāĻļā§ āύāĻŋāĻā§āϰ āĻŦāĻŋāώā§āĻā§āϞ⧠āϞā§āĻāĻž āϰā§ā§āĻā§ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤
Diagnosis 1
Old PCL Injury â āĻĒā§āϰā§āύ⧠Posterior Cruciate Ligament Injury
āĻšāĻžāĻāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻā§āϰā§āĻļāĻŋā§ā§āĻ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻāĻžāϤāĨ¤
Confidence: 0.89
Diagnosis 2
OA Knee â Osteoarthritis of Knee
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻāĻŋāĻāĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏ āĻŦāĻž āĻšāĻžāĻāĻā§āϰ āĻā§ā§āύā§āĻā§āϰ āĻā§āώā§āĻāύāĻŋāϤ āϰā§āĻāĨ¤
Confidence: 0.86
Diagnosis 3
Old Tibial Plateau Fracture â āĻāĻŋāĻŦāĻŋā§āĻžāϞ āĻĒā§āϞā§āϝāĻžāĻā§āϰ āĻĒā§āϰā§āύ⧠āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰ
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āĻā§ā§āύā§āĻā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ Tibia āĻšāĻžā§ā§āϰ āĻāĻĒāϰā§āϰ āĻĒā§āώā§āĻ ā§ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻžāĻāύāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Fracture-āĻāϰ āĻāϞā§āϞā§āĻ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āϏā§āĻĒāώā§āĻāĨ¤ āϤāĻŦā§ āĻĄāĻžāύ āύāĻž āĻŦāĻžāĻŽ āĻšāĻžāĻāĻā§âāϏā§āĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻĒā§āĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Confidence: 0.88 for fracture history; 0.50 for laterality.
đŠ PART 3 â MY INDEPENDENT CLINICAL ASSESSMENT
10. Final Working Diagnosis â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Primary Working Diagnosis
Chronic Posterior Cruciate Ligament (PCL) Injury / Possible Chronic PCL Insufficiency of the Knee, with Suspected Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻšāĻžāĻāĻā§āϰ āĻĒā§āϰā§āύ⧠Posterior Cruciate Ligament āĻāĻāĻžāϤāĻāύāĻŋāϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Tibial Plateau Fracture-āĻāϰ āĻĒāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Post-Traumatic OsteoarthritisāĨ¤
Overall Diagnostic Confidence: 0.76 â Provisional, not confirmed.
Why this diagnosis?
āĻāĻ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāĻā§āώ⧠āĻāĻžāϰāĻāĻŋ āĻĒā§āϰāϧāĻžāύ Clinical Clue āϰā§ā§āĻā§āĨ¤
1. Previous PCL Injury: āĻĒā§āϰā§āύ⧠āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āĻāĻāĻžāϤā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
2. Previous Tibial Plateau Fracture: āĻšāĻžāĻāĻā§āϰ āĻā§ā§āύā§āĻā§āϰ āĻšāĻžā§ā§ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻāĻžāϤāĨ¤
3. Possible Positive Posterior Drawer Test: PCL insufficiency-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒāϰā§āĻā§āώāĻžāĻāϤ āĻĒā§āϰāĻŽāĻžāĻŖāĨ¤
4. Thigh Muscle Wasting: āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāĻžāĻāĻā§āϰ āϏāĻŽāϏā§āϝāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻļāĻžāϰā§āϰāĻŋāĻ āĻāĻŋāĻšā§āύāĨ¤
Clinical Limitation
āĻŦāϰā§āϤāĻŽāĻžāύ MRI, X-ray āĻāĻŦāĻ āĻĒā§āϰā§āĻŖāĻžāĻā§āĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻĨā§āϝ āĻāĻžā§āĻž Osteoarthritis-āĻāϰ stage, PCL tear-āĻāϰ grade āĻāĻŦāĻ fracture-āĻāϰ healing status āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
11. Definition â āϰā§āĻā§āϰ āϏāĻāĻā§āĻāĻž
A. Posterior Cruciate Ligament Injury
Posterior Cruciate Ligament āĻšāϞ⧠āĻšāĻžāĻāĻā§āϰ āĻāĻāĻāĻŋ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ, āϝāĻž Femur āĻ Tibia-āĻāϰ āĻŽāϧā§āϝ⧠āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻŦāĻāĻžā§ āϰāĻžāĻā§āĨ¤
āĻāĻ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ āĻāĻāĻļāĻŋāĻ āĻŦāĻž āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšāϞ⧠āϤāĻžāĻā§ PCL Injury āĻŦāϞāĻž āĻšā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§ āĻāĻāĻžāϤ āĻŦāĻž āĻāĻŋāĻā§ā§ āϝāĻžāĻā§āĻžāĨ¤
B. Post-Traumatic Osteoarthritis
Post-Traumatic Osteoarthritis āĻšāϞ⧠āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻā§ā§āύā§āĻā§āϰ āĻāĻāĻžāϤ, āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰ āĻŦāĻž āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ āĻā§āώāϤāĻŋāϰ āĻĒāϰ āĻā§ā§āύā§āĻā§āϰ Cartilage āĻ āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻāĻžāĻ āĻžāĻŽā§ā§ āĻā§āώā§āĻāύāĻŋāϤ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻžāϤā§āϰ āĻĒāϰāĻŦāϰā§āϤ⧠āϏāĻŽā§ā§ āĻšāĻžāĻāĻā§āϰ āĻā§ā§āύā§āĻā§āϰ āĻā§āώā§āĻāύāĻŋāϤ āĻŦāĻžāϤāĨ¤
C. Tibial Plateau Fracture
Tibia āĻšāĻžā§ā§āϰ āĻāĻĒāϰā§āϰ āϝ⧠āĻ āĻāĻļ āĻšāĻžāĻāĻā§āϰ Joint Surface āϤā§āϰāĻŋ āĻāϰā§, āϏā§āĻāĻžāύ⧠āĻāĻžāĻāύāĻā§ Tibial Plateau Fracture āĻŦāϞāĻž āĻšā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āύāĻŋāĻā§āϰ āĻā§ā§āύā§āĻ-āĻĒā§āώā§āĻ ā§āϰ āĻšāĻžā§ āĻā§āĻā§ āϝāĻžāĻā§āĻžāĨ¤
Confidence: 0.98 for definitions.
12. Etiology & Pathophysiology â āĻāĻžāϰāĻŖ āĻ āϰā§āĻā§āϰ āĻŦāĻŋāĻāĻžāĻļ
Possible Injury Mechanism
PCL injury āϏāĻžāϧāĻžāϰāĻŖāϤ āĻšāϤ⧠āĻĒāĻžāϰā§:
- āĻšāĻžāĻāĻā§ āĻāĻžāĻāĻ āĻĨāĻžāĻāĻž āĻ āĻŦāϏā§āĻĨāĻžā§ Tibia-āĻāϰ āϏāĻžāĻŽāύā§āϰ āĻ āĻāĻļā§ āϏāϰāĻžāϏāϰāĻŋ āĻāĻāĻžāϤāĨ¤
- āϏā§āĻ āĻĻā§āϰā§āĻāĻāύāĻžā§ Dashboard InjuryāĨ¤
- āĻā§āϞāĻžāϧā§āϞāĻžā§ āĻĒā§ā§ āϝāĻžāĻā§āĻžāĨ¤
- āĻšāĻžāĻāĻā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ HyperflexionāĨ¤
Pathophysiology
Previous Trauma â PCL Damage / Tibial Plateau Injury â Altered Knee Biomechanics â Abnormal Joint Loading â Possible Cartilage Degeneration â Post-Traumatic Osteoarthritis
āĻŦāĻžāĻāϞāĻžā§:
āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻāĻžāϤ â āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ āĻŦāĻž āĻšāĻžā§ā§āϰ āĻā§āώāϤāĻŋ â āĻšāĻžāĻāĻā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāϰāĻŦāĻšāύ āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ â āĻā§ā§āύā§āĻā§ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāĻĒ â Cartilage āĻā§āώā§ā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž â Post-Traumatic OsteoarthritisāĨ¤
āĻāĻ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻā§āϝāĻž; āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻŽāύ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāĻā§āĻā§ āĻāĻŋ āύāĻž, āϤāĻž imaging āĻ clinical assessment āĻĻāĻŋā§ā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.93 for the established mechanism; 0.75 for its application to this patient.
13. Clinical Features â āϰā§āĻā§āϰ āϞāĻā§āώāĻŖ
Chronic PCL Injury āĻāĻŦāĻ Post-Traumatic OA-āϤ⧠āύāĻŋāĻā§āϰ āϞāĻā§āώāĻŖ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§:
| Clinical Feature | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠|
|---|---|---|
| Knee Pain | āĻšāĻžāĻāĻā§āĻŦā§āϝāĻĨāĻž | āϏāĻŽā§āĻāĻžāĻŦā§āϝ, āϏāϰāĻžāϏāϰāĻŋ āϞā§āĻāĻž āύā§āĻ |
| Instability | āĻšāĻžāĻāĻā§ āĻĸāĻŋāϞ⧠āϞāĻžāĻāĻž | āϏāĻŽā§āĻāĻžāĻŦā§āϝ |
| Thigh Muscle Wasting | āĻāϰā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻāĻŽā§ āϝāĻžāĻā§āĻž | āϏāĻŽā§āĻāĻŦāϤ āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§ |
| Posterior Drawer Positive | āĻšāĻžāĻāĻā§āϰ āĻĒā§āĻāύā§āϰ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāϰ āĻĒāϰā§āĻā§āώāĻž āĻĒāĻāĻŋāĻāĻŋāĻ | āϏāĻŽā§āĻāĻŦāϤ āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§ |
| Reduced ROM | āĻšāĻžāĻāĻā§āϰ āύā§āĻžāĻā§āĻž āĻāĻŽā§ āϝāĻžāĻā§āĻž | āĻāĻžāύāĻž āύā§āĻ |
| Crepitus | āĻšāĻžāĻāĻā§ āύāĻžā§āĻžāϞ⧠āĻāϰā§āώāĻŖā§āϰ āĻļāĻŦā§āĻĻ āĻŦāĻž āĻ āύā§āĻā§āϤāĻŋ | āĻāĻžāύāĻž āύā§āĻ |
| Joint Effusion | āĻšāĻžāĻāĻā§āϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āϤāϰāϞ | āĻāĻžāύāĻž āύā§āĻ |
| Activity-related Pain | āĻšāĻžāĻāĻāĻžāĻāϞāĻžā§ āĻŦā§āϝāĻĨāĻž āĻŦā§āĻĻā§āϧāĻŋ | āĻāĻžāύāĻž āύā§āĻ |
Confidence: 0.94 for general clinical features; patient-specific confidence varies as shown.
đ§ PART 4 â INVESTIGATIONS
14. Doctor’s Requested Investigations â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĻā§āĻā§āĻž āĻĒāϰā§āĻā§āώāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āϏāĻŽā§āĻāĻŦāϤ āĻĻā§āĻāĻŋ āĻĒāϰā§āĻā§āώāĻž āϞā§āĻāĻž āĻšā§ā§āĻā§āĨ¤
Investigation 1: MRI of Knee
MRI â Magnetic Resonance Imaging
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŽā§āĻŦāĻā§ā§ āϤāϰāĻā§āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰ⧠āĻšāĻžāĻāĻā§āϰ āĻā§āϤāϰā§āϰ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ, āĻŽā§āύāĻŋāϏā§āĻāĻžāϏ āĻāĻŦāĻ āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻāĻŦāĻŋāĨ¤
Purpose:
- PCL Injury āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
- Partial āĻŦāĻž Complete Tear āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
- Meniscal Injury āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
- Cartilage Damage āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
- āĻ āύā§āϝāĻžāύā§āϝ Ligament Injury āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
Doctor’s likely intention: āĻĒā§āϰā§āύ⧠PCL injury-āĻāϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻž āĻ associated internal derangement āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Confidence: 0.91
Investigation 2: X-ray of Knee
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠X-ray of Knee āĻāĻŦāĻ āϏāĻŽā§āĻāĻŦāϤ B/V āĻŦāĻž āĻĻā§āĻāĻŋ View āϞā§āĻāĻž āϰā§ā§āĻā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āĻšāĻžā§ āĻ āĻā§ā§āύā§āĻā§āϰ āĻāĻā§āϏ-āϰā§āĨ¤
Purpose:
- Previous Tibial Plateau Fracture-āĻāϰ āĻ āĻŦāϏā§āĻĨāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
- Joint-space narrowing āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
- Osteophyte āĻŦāĻž āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻšāĻžā§ā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻĻā§āĻāĻžāĨ¤
- Malalignment āĻŦāĻž āĻšāĻžā§ā§āϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
- āϏāĻŽā§āĻāĻžāĻŦā§āϝ Post-Traumatic Osteoarthritis-āĻāϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
Suggested appropriate views: Weight-bearing AP āĻ lateral knee radiographs; āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻ āύā§āϝāĻžāύā§āϝ viewāĨ¤
Confidence: 0.89 for X-ray being requested; 0.65 for the exact handwritten views.
Additional Investigations â āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻĒāϰā§āĻā§āώāĻž
| Investigation | Purpose | Indication |
|---|---|---|
| PCL Stress Radiograph | Posterior tibial translation āĻŽā§āϞā§āϝāĻžā§āύ | Clinically significant PCL laxity |
| Serum Creatinine/eGFR | Kidney function | Oral NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ āĻā§āĻāĻāĻŋ āĻĨāĻžāĻāϞ⧠|
| CBC | Anaemia āĻŦāĻž systemic abnormality | Clinical indication āĻĨāĻžāĻāϞ⧠|
| ESR/CRP | Inflammatory process āĻŽā§āϞā§āϝāĻžā§āύ | Inflammatory arthritis āĻŦāĻž infection āϏāύā§āĻĻā§āĻš āĻšāϞ⧠|
| Vitamin D | Vitamin D deficiency āĻŽā§āϞā§āϝāĻžā§āύ | Deficiency-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻž āĻāĻĒāϏāϰā§āĻ āĻĨāĻžāĻāϞ⧠|
Important: āĻāĻā§āϞ⧠āϰā§āĻā§āϰ āĻāύā§āϝ āύāϤā§āύ āĻāϰ⧠āĻĻā§āĻā§āĻž āĻĒāϰā§āĻā§āώāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āύā§āĨ¤ Clinical indication āĻ āύā§āϝāĻžā§ā§ āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
Confidence: 0.94
15. Differential Diagnosis â āĻŦāĻŋāĻāϞā§āĻĒ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻ
| Diagnosis | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Clinical Reasoning | Confidence |
|---|---|---|---|
| Chronic PCL Insufficiency | āĻĒā§āϰā§āύ⧠PCL āĻāĻāĻžāϤā§āϰ āĻāĻžāϰāĻŖā§ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻž | Historical PCL injury āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ PD test positive | 0.83 |
| Post-Traumatic Knee OA | āĻāĻāĻžāϤ-āĻĒāϰāĻŦāϰā§āϤ⧠āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻāĻŋāĻāĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏ | Previous fracture āĻ physician-documented OA | 0.76 |
| Meniscal Injury | āĻšāĻžāĻāĻā§āϰ āĻŽā§āύāĻŋāϏā§āĻāĻžāϏ⧠āĻāĻāĻžāϤ | Previous knee trauma; locking history unavailable | 0.50 |
| Residual Fracture Deformity | āĻĒā§āϰā§āύ⧠āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āĻšāĻžā§ā§āϰ āĻāĻā§āϤāĻŋ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | Tibial plateau fracture history | 0.55 |
| Other Ligament Injury | āĻšāĻžāĻāĻā§āϰ āĻ āύā§āϝ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§ āĻāĻāĻžāϤ | Combined injury cannot be excluded | 0.50 |
Clinical priority: PCL injury-āĻāϰ āϏā§āĻĨāĻžā§āĻŋāϤā§āĻŦ āĻ āĻā§āϰā§āϤā§āĻŦ āĻāĻŦāĻ Post-Traumatic OA-āĻāϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ āϝāĻžāĻāĻžāĻ āĻāϰāĻžāĨ¤
đŠ PART 5 â DOCTOR’S DX VS INDEPENDENT DX
16. Diagnostic Comparison â āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āϤā§āϞāύāĻž
- đĸ Old PCL Injury: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻŋāĻāĻŋāϤ Dx āĻāĻŦāĻ āϏā§āĻŦāĻžāϧā§āύ working assessment āĻāĻāĻŽāϤāĨ¤ āϤāĻŦā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻž āĻāĻāĻļāĻŋāĻ Tear āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύā§āĨ¤ Confidence: 0.89
- đĸ Knee Osteoarthritis: āĻāĻŋāĻāĻŋā§āϏāĻ OA Knee āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύ āĻŦāϞ⧠āĻŽāύ⧠āĻšāĻā§āĻā§āĨ¤ āϏā§āĻŦāĻžāϧā§āύ āĻŽā§āϞā§āϝāĻžā§āύā§āĻ OA āϏāĻŽā§āĻāĻžāĻŦā§āϝāĨ¤ Confidence: 0.86
- đĸ Old Tibial Plateau Fracture: āĻāĻā§ āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰā§āϰ āĻā§āϰā§āϤā§āĻŦ āϏā§āĻŦā§āĻā§āϤāĨ¤ Confidence: 0.88
- đ Post-Traumatic Osteoarthritis: āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻŽā§āĻāĻŦāϤ āĻļā§āϧ⧠OA āϞāĻŋāĻā§āĻā§āύāĨ¤ āϏā§āĻŦāĻžāϧā§āύ āĻŽā§āϞā§āϝāĻžā§āύ⧠āĻĒā§āϰā§āύ⧠āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰ āĻ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āĻāĻāĻžāϤā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻāĻŋāĻā§ Post-Traumatic OA āĻšāĻŋāϏā§āĻŦā§ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤ āĻāĻāĻŋ āĻāĻāĻāĻŋ clinical inference, āύāĻŋāĻļā§āĻāĻŋāϤ diagnosis āύā§āĨ¤ Confidence: 0.76
- đ Chronic PCL Insufficiency: āĻĒā§āϰā§āύ⧠PCL injury āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ positive posterior drawer test āĻĨā§āĻā§ āϏā§āĻĨāĻžā§ā§ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤ āĻāĻŋāύā§āϤ⧠Objective laxity measurement āύā§āĻāĨ¤ Confidence: 0.72
Final Comparison
Doctor’s Diagnosis and Independent Working Diagnosis: Substantially Similar.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāĻŦāĻ āϏā§āĻŦāĻžāϧā§āύ Clinical Assessment āĻŽā§āϞāϤ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
āĻĒāĻžāϰā§āĻĨāĻā§āϝ āĻšāϞ⧠āϏā§āĻŦāĻžāϧā§āύ āĻŽā§āϞā§āϝāĻžā§āύ⧠āϰā§āĻāĻāĻŋāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻāĻžāϤāĻāύāĻŋāϤ āĻāĻžāϰāĻŖ āĻāĻŦāĻ Chronic Instability-āĻāϰ āĻŦāĻŋāώā§āĻāĻŋ āϏā§āĻĒāώā§āĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Overall Comparison Confidence: 0.86
đ§ PART 6 â MEDICATION REVIEW ACCORDING TO MEDEX BANGLADESH
Table 1: Prescribed Drug Identification
| No. | Brand Name | Generic Name | Therapeutic Class | MedEx Unit Price |
|---|---|---|---|---|
| 1 | Ternilla 100 mg | Aceclofenac | NSAID | ā§ŗ5 |
| 2 | Maxpro MUPS 20 mg | Esomeprazole | Proton Pump Inhibitor | ā§ŗ10 |
| 3 | Ostocal DX | Calcium + Vitamin D3 | Mineral & Vitamin Supplement | ā§ŗ10 |
| 4 | Arthrosin TS | Glucosamine Sulfate + Chondroitin | Stimulation of Cartilage Formation | ā§ŗ30 |
Price confidence: 0.99 â MedEx-listed prices checked on 28 October 2026.
Prescription safety note: āĻāĻŦāĻŋāϰ handwritten dosing āĻ duration āĻĒā§āϰā§āĻĒā§āϰāĻŋ āĻĒāĻžāĻ āϝā§āĻā§āϝ āύā§āĨ¤ āϤāĻžāĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻŦāϞ⧠āĻā§āύ⧠āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻĄā§āĻ āĻĻāĻžāĻŦāĻŋ āĻāϰāĻž āĻšāĻā§āĻā§ āύāĻžāĨ¤
đ DRUG 1 â TERNILLA 100 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Aceclofenac 100 mg â āĻāϏāĻŋāĻā§āϞā§āĻĢā§āύāĻžāĻāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Ternilla â āĻāĻžāϰāύāĻŋāϞāĻžāĨ¤
Manufacturer: Healthcare Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
A-Pak, Acebid āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Aceclofenac 100 mg āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; Non-steroidal Anti-inflammatory Drugs (NSAIDs).
āĻŦāĻžāĻāϞāĻž: āĻā§ā§āύā§āĻā§āϰ āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āϰ āύāύ-āϏā§āĻā§āϰā§āĻĄāĻžāϞ āĻāώā§āϧāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Phenylacetic acid derivative NSAID.
āĻŦāĻžāĻāϞāĻž: NSAID āĻļā§āϰā§āĻŖāĻŋāϰ āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis āĻāĻŦāĻ āĻāĻāĻžāϤāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽāĻžāύā§āĨ¤
7. Why Prescribed in This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻšāĻžāĻāĻā§āĻŦā§āϝāĻĨāĻž āĻ Osteoarthritis-āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻāύā§āϝāĨ¤
Clinical point: Aceclofenac āĻŦā§āϝāĻĨāĻž āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠PCL Tear āĻā§ā§āĻž āϞāĻžāĻāĻžā§ āύāĻžāĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Dyspepsia, abdominal pain, nausea, dizziness āĻāĻŦāĻ gastrointestinal irritationāĨ¤
āĻā§āϰā§āϤāϰ āĻā§āĻāĻāĻŋāϰ āĻŽāϧā§āϝ⧠GI bleeding, acute kidney injury āĻāĻŦāĻ cardiovascular complications āϰā§ā§āĻā§āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ MedEx
10. Unit Price, Strip Price & Composition â āĻĻāĻžāĻŽ āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻļāĻā§āϤāĻŋ
Unit Price: ā§ŗ5.00
Strip Price: ā§ŗ50.00
Also available: Ternilla SR 200 mg.
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Aceclofenac Cyclooxygenase enzyme-āĻāϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻŦāĻžāϧāĻž āĻĻāĻŋā§ā§ Prostaglandin synthesis āĻāĻŽāĻžā§āĨ¤
āĻĢāϞ⧠āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŽā§āĨ¤
12. Drug Indications â āϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis āĻāĻŦāĻ āĻŦāĻŋāĻāĻŋāύā§āύ Musculoskeletal PaināĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Anticoagulants, Lithium, Methotrexate, Diuretics āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ NSAID-āĻāϰ āϏāĻā§āĻā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ interaction āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
NSAID-induced asthma, active GI bleeding āĻ āĻĨāĻŦāĻž NSAID hypersensitivity āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āύā§āĻĒāϝā§āĻā§āϤāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Renal disease, liver disease, peptic ulcer, cardiovascular disease āĻāĻŦāĻ uncontrolled hypertension āĻĨāĻžāĻāϞ⧠āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻĒā§āϰā§ā§āĻ
MedEx reference adult dose: 100 mg twice daily.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ adult reference āĻ āύā§āϝāĻžā§ā§ ā§§ā§Ļā§Ļ āĻŽāĻŋ.āĻā§āϰāĻž. āĻĻāĻŋāύ⧠āĻĻā§āĻāĻŦāĻžāϰāĨ¤
āĻāĻāĻŋ āϰā§āĻā§āϰ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āύāĻŋāĻļā§āĻāĻŋāϤ āĻĄā§āĻ āύā§āĨ¤ OA-āϤ⧠Oral NSAID āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠Lowest Effective Dose āĻāĻŦāĻ Shortest Possible Duration āĻ āύā§āϏāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Pregnancy-āϤ⧠NSAID āĻŦāĻŋāĻļā§āώāϤ ⧍ā§Ļ āϏāĻĒā§āϤāĻžāĻšā§āϰ āĻĒāϰ āĻā§āĻāĻāĻŋāĻĒā§āϰā§āĻŖ āĻšāϤ⧠āĻĒāĻžāϰā§; āĻĒāϰāĻŦāϰā§āϤ⧠āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāϰāĻŋāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤ Lactation-āĻ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āϏāĻāĻŽāĻŋāĻļā§āϰāĻŖ
Aceclofenac-āĻāϰ āĻŦāĻŋāĻāĻŋāύā§āύ Fixed-Dose Combination āĻŦāĻžāĻāĻžāϰ⧠āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§; āϤāĻŦā§ āĻāĻāĻ Generic-āĻāϰ āĻ āύā§āϝ combination āĻāĻŦāĻ āĻāĻāĻ āĻāώā§āϧā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ brand āĻāĻ āĻŦāĻŋāώ⧠āύā§āĨ¤ āĻāĻ āĻĒā§āϰāϤāĻŋāĻŦā§āĻĻāύ⧠MedEx-verified monotherapy āĻ SR formulation āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Drug Identification Confidence: 0.99
Patient-specific Indication Confidence: 0.90
Source: MedEx â Ternilla 100 mg.
đ DRUG 2 â MAXPRO MUPS 20 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Esomeprazole 20 mg â āĻāϏā§āĻŽāĻŋāĻĒā§āϰāĻžāĻāϞāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Maxpro MUPS â āĻŽā§āϝāĻžāĻā§āϏāĻĒā§āϰ⧠āĻŽāĻžāĻĒāϏāĨ¤
Manufacturer: Renata PLC.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Nexum MUPS, Maxima MUPS, Emep MUPSāĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Proton Pump Inhibitor (PPI).
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϏāĻŋāĻĄ āĻā§āĻĒāĻžāĻĻāύ āĻāĻŽāĻžāύā§āϰ āĻāώā§āϧāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Substituted Benzimidazole Proton Pump Inhibitor.
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
GERD, Gastric Ulcer, Duodenal Ulcer āĻāĻŦāĻ NSAID-associated gastric ulcer āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why Prescribed in This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§
Aceclofenac āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽā§ āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϞāϏāĻžāϰ āĻ āĻāĻāĻŋāϞāϤāĻžāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāϤ⧠Gastroprotection āĻšāĻŋāϏā§āĻŦā§ āĻĻā§āĻā§āĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦā§āĻļāĻŋāĨ¤
āĻāĻāĻŋ āϰā§āĻā§āϰ GERD āϰā§ā§āĻā§âāĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Headache, nausea, abdominal pain, diarrhoea, constipationāĨ¤
āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠āĻāĻŋāĻā§ āϰā§āĻā§āϰ Hypomagnesaemia, Vitamin B12 deficiency āĻ āĻĨāĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāĻāĻŋāϞāϤāĻžāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ MedEx
10. Unit Price, Strip Price & Composition â āĻĻāĻžāĻŽ āĻ āĻļāĻā§āϤāĻŋ
Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ140.00
Also available: Maxpro MUPS 40 mg.
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Gastric Parietal Cell-āĻāϰ Hâē/Kâē-ATPase Proton Pump āĻŦāύā§āϧ āĻāϰ⧠Acid Secretion āĻāĻŽāĻžā§āĨ¤
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϏāĻŋāĻĄ āϤā§āϰāĻŋāϰ āĻĒā§āϰāϧāĻžāύ āĻāύāĻāĻžāĻāĻŽā§āϰ āĻāĻžāĻ āĻŦāύā§āϧ āĻāϰā§āĨ¤
12. Drug Indications â āϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ
GERD, Erosive Esophagitis, Peptic Ulcer āĻāĻŦāĻ NSAID-associated gastric ulcer preventionāĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Clopidogrel-āĻāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻāĻŽāĻžāύā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž, Warfarin monitoring-āĻāϰ āĻĒā§āϰā§ā§āĻāύ, Methotrexate interaction āĻāĻŦāĻ āĻāĻŋāĻā§ āĻāώā§āϧā§āϰ absorption āĻĒāϰāĻŋāĻŦāϰā§āϤāύā§āϰ āĻā§āĻāĻāĻŋ āϰā§ā§āĻā§āĨ¤
Known hypersensitivity āĻāĻāĻāĻŋ contraindicationāĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Severe hepatic disease, unexplained weight loss, GI bleeding āĻāĻŦāĻ āĻĻā§āϰā§āĻāĻŽā§ā§āĻžāĻĻāĻŋ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻĒā§āϰā§ā§āĻ
MedEx reference: NSAID-associated gastric ulcer risk reduction-āĻāϰ āĻāύā§āϝ Esomeprazole 20 mg once daily āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
MUPS tablet āĻāĻŋāĻŦāĻžāύ⧠āĻŦāĻž āĻā§āĻā§āĻž āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤ āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠āĻŦā§āϰā§āϝāĻžāύā§āĻĄā§āϰ āĻ āύā§āĻŽā§āĻĻāĻŋāϤ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻ āύā§āϝāĻžā§ā§ āĻĒāĻžāύāĻŋāϤ⧠disperse āĻāϰāĻž āϝāĻžā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
Pregnancy āĻ lactation-āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ RiskâBenefit Assessment āĻĒā§āϰā§ā§āĻāύāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āϏāĻāĻŽāĻŋāĻļā§āϰāĻŖ
MedEx-āĻ Esomeprazole-āĻāϰ āϏāĻā§āĻā§ Naproxen āĻāĻŦāĻ H. pylori eradication-āĻāϰ āĻāύā§āϝ Amoxicillin āĻ Clarithromycin-āϏāĻāĻā§āϰāĻžāύā§āϤ combination formulations āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϰā§ā§āĻā§āĨ¤
Drug Identification Confidence: 0.99
Reason for Prescription Confidence: 0.94
Source: MedEx â Maxpro MUPS 20 mg.
đ DRUG 3 â OSTOCAL DX
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Conventional Calcium + Vitamin D3.
Composition: Elemental Calcium 600 mg + Vitamin D3 400 IU.
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Ostocal DX â āĻ
āϏā§āĻā§āĻā§āϝāĻžāϞ āĻĄāĻŋāĻāĻā§āϏāĨ¤
Manufacturer: Eskayef Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Ostogen D Forte, Ostoplus-DX āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ CalciumâVitamin D formulationsāĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Specific Mineral & Vitamin Combined Preparations.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāύāĻŋāĻ āĻ āĻāĻŋāĻāĻžāĻŽāĻŋāύā§āϰ āϏāĻŽāύā§āĻŦāĻŋāϤ āϏāĻžāĻĒā§āϞāĻŋāĻŽā§āύā§āĻāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Mineral Supplement + Fat-Soluble Vitamin.
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
Calcium āĻ Vitamin D deficiency āϏāĻāĻļā§āϧāύ, Osteoporosis āĻ Osteomalacia management-āĻāϰ āϏāĻšāĻžā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why Prescribed in This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§
āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Fracture-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏā§āϰ āĻāĻžāϰāĻŖā§ āĻšāĻžā§ā§āϰ āĻĒā§āώā§āĻāĻŋāĻāϤ āϏāĻšāĻžā§āϤāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Important: Calcium āĻ Vitamin D supplement āϏāϰāĻžāϏāϰāĻŋ PCL Tear āĻ āĻĨāĻŦāĻž Knee Osteoarthritis āϏāĻžāϰāĻžā§ āύāĻžāĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Constipation, nausea, abdominal discomfortāĨ¤
āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϰāĻšāĻŖā§ Hypercalcaemia āĻāĻŦāĻ Kidney Stone-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ MedEx
10. Unit Price, Strip Price & Composition â āĻĻāĻžāĻŽ āĻ āĻļāĻā§āϤāĻŋ
Unit Price: ā§ŗ10.00
Strip Price: ā§ŗ60.00
Also available: Ostocal D 500 mg + 200 IUāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Calcium āĻšāĻžā§ā§āϰ Mineralisation-āĻ āĻ āĻāĻļāĻā§āϰāĻšāĻŖ āĻāϰā§āĨ¤
Vitamin D3 āĻ āύā§āϤā§āϰ āĻĨā§āĻā§ Calcium Absorption āĻŦāĻžā§āĻžā§ āĻāĻŦāĻ Calcium Homeostasis āĻŦāĻāĻžā§ āϰāĻžāĻāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
12. Drug Indications â āϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ
Calcium deficiency, Vitamin D deficiency, Osteoporosis, Osteomalacia āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ Metabolic Bone DisordersāĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Tetracyclines, āĻāĻŋāĻā§ Quinolone Antibiotics, Levothyroxine, Digoxin āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Calcium/Vitamin D preparation-āĻāϰ āϏāĻā§āĻā§ interaction āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšā§āĨ¤
Hypercalcaemia āĻ āĻāĻŋāĻā§ āϧāϰāύā§āϰ Renal Stone Disease-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āύā§āĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Chronic Kidney Disease, Hypercalciuria, Kidney Stones āĻāĻŦāĻ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ Vitamin D āĻā§āϰāĻšāĻŖā§āϰ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻĒā§āϰā§ā§āĻ
MedEx-āĻ CalciumâVitamin D preparation-āĻāϰ āĻŦāĻŋāĻāĻŋāύā§āύ strength āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāύā§āύ dosing āĻĻā§āĻā§āĻž āĻāĻā§āĨ¤
āĻāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ handwritten dose āĻ āϏā§āĻĒāώā§āĻāĨ¤ āϤāĻžāĻ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻŽā§āĻ Dietary Calcium Intake āĻāĻŦāĻ Supplement Dose āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
āĻĒā§āϰā§ā§āĻāύ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§āĨ¤ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ Calcium/Vitamin D āĻā§āĻŋā§ā§ āĻāϞāϤ⧠āĻšāĻŦā§āĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āϏāĻāĻŽāĻŋāĻļā§āϰāĻŖ
Calcium + Vitamin D3 + Multiminerals āĻāĻŦāĻ Calcium-āĻāϰ āĻŦāĻŋāĻāĻŋāύā§āύ āĻĒā§āϰāϏā§āϤā§āϤāĻŋ MedEx-āĻ āϰā§ā§āĻā§āĨ¤
Drug Identification Confidence: 0.99
Patient-specific Indication Confidence: 0.72
Source: MedEx â Ostocal DX.
đ DRUG 4 â ARTHROSIN TS
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Glucosamine Sulfate 750 mg + Chondroitin 600 mg.
āĻŦāĻžāĻāϞāĻž: āĻā§āϞā§āĻā§āϏāĻžāĻŽāĻŋāύ āϏāĻžāϞāĻĢā§āĻ āĻ āĻāύāĻĄā§āϰā§āĻāĻŋāύāĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Arthrosin TS â āĻāϰā§āĻĨā§āϰā§āϏāĻŋāύ āĻāĻŋāĻāϏāĨ¤
Manufacturer: UniMed UniHealth Pharmaceuticals Ltd.
3. MedEx Alternate Brand â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Arth-A TS, Carticare TS, Synflex TS āĻāĻŦāĻ āĻ āύā§āϰā§āĻĒ GlucosamineâChondroitin combinationāĨ¤
4. MedEx Therapeutic Class â āĻĨā§āϰāĻžāĻĒāĻŋāĻāĻāĻŋāĻ āĻļā§āϰā§āĻŖāĻŋ
Stimulation of Cartilage Formation.
āĻŦāĻžāĻāϞāĻž: Cartilage formation-āĻāϰ āϏāĻšāĻžā§āĻ āĻĒā§āϰāϏā§āϤā§āϤāĻŋ āĻšāĻŋāϏā§āĻŦā§ āĻļā§āϰā§āĻŖāĻŋāĻŦāĻĻā§āϧāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Symptomatic Slow-Acting Joint Supplement / Glycosaminoglycan-related Preparation.
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
MedEx āĻ āύā§āϝāĻžā§ā§ Osteoarthritis-āĻ Joint Supplement āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤
7. Why Prescribed in This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§
āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻŽā§āĻāĻŦāϤ Knee Osteoarthritis-āĻāϰ āĻāĻĒāϏāϰā§āĻ āύāĻŋā§āύā§āϤā§āϰāĻŖ āĻ āĻā§ā§āύā§āĻā§āϰ āϏāĻšāĻžā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšāĻŋāϏā§āĻŦā§ Arthrosin TS āĻĻāĻŋā§ā§āĻā§āύāĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
Nausea, abdominal discomfort, flatulence āĻāĻŦāĻ āĻāĻŋāĻā§ āĻā§āώā§āϤā§āϰ⧠allergic reactionāĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ MedEx
10. Unit Price, Strip Price & Composition â āĻĻāĻžāĻŽ āĻ āĻļāĻā§āϤāĻŋ
Unit Price: ā§ŗ30.00
Strip Price: ā§ŗ180.00
Also available: Arthrosin 250 mg + 200 mgāĨ¤
11. Mechanism of Action â āĻāĻžāϰā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ
Glucosamine āĻ Chondroitin āĻšāϞ⧠Cartilage Matrix-āĻāϰ Glycosaminoglycan-āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻāĻĒāĻžāĻĻāĻžāύāĨ¤
āϤāĻžāϤā§āϤā§āĻŦāĻŋāĻāĻāĻžāĻŦā§ Cartilage metabolism āĻ Proteoglycan synthesis-āĻ āĻā§āĻŽāĻŋāĻāĻž āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ Supplement āĻā§āϰāĻšāĻŖ āĻāϰāϞ⧠clinically meaningful Cartilage Regeneration āĻšā§âāĻāĻŽāύ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āύā§āĨ¤
12. Drug Indications â āϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ
MedEx product information āĻ āύā§āϝāĻžā§ā§ Knee, Hip āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Joint Osteoarthritis-āĻ Supplement āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
13. Drug Interactions & Contraindications â āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧ
Warfarin-āĻāϰ āϏāĻā§āĻā§ Bleeding Risk āĻŦā§āĻĻā§āϧāĻŋ āĻĒā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Glucosamine āĻŦāĻž Chondroitin-āĻāϰ āĻāĻĒāĻžāĻĻāĻžāύ⧠hypersensitivity āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻŋā§ā§ āĻāϞāϤ⧠āĻšāĻŦā§āĨ¤
14. Precautions & Warnings â āϏāϤāϰā§āĻāϤāĻž
Diabetes, Severe Renal Disease āĻāĻŦāĻ Liver Disease āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
15. Dosage & Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻĒā§āϰā§ā§āĻ
MedEx reference: 750 mg + 600 mg, one tablet twice daily.
āĻāĻāĻŋ āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻā§āϰ reference dose; āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āύāϤā§āύ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻĻā§āĻļ āύā§āĨ¤
16. Pregnancy & Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
āĻĒāϰā§āϝāĻžāĻĒā§āϤ Safety Data āύā§āĻāĨ¤ āϤāĻžāĻ Pregnancy āĻ Lactation-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§āĻŋā§ā§ āĻāϞāĻž āĻāĻāĻŋāϤāĨ¤
17. Other Combinations â āĻ āύā§āϝāĻžāύā§āϝ āϏāĻāĻŽāĻŋāĻļā§āϰāĻŖ
MedEx-āĻ Glucosamine Sulfate + Diacerein āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ Glucosamine-containing formulations āϰā§ā§āĻā§āĨ¤
đ Important Guideline Difference
MedEx product information-āĻ Arthrosin TS-āĻāϰ OA-related indication āĻāϞā§āϞā§āĻ āĻĨāĻžāĻāϞā§āĻ NICE NG226 Glucosamine āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻāϰāĻžāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻā§ā§āĨ¤
āĻāĻžāϰāĻŖ Osteoarthritis-āĻāϰ āĻāĻĒāϏāϰā§āĻā§ clinically meaningful benefit-āĻāϰ āĻļāĻā§āϤ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
Therefore: MedEx therapeutic classification āĻŦāĻž manufacturer’s indication-āĻā§ āĻāύā§āϤāϰā§āĻāĻžāϤāĻŋāĻ Guideline-supported effectiveness-āĻāϰ āϏāĻŽāϤā§āϞā§āϝ āϧāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Drug Identification Confidence: 0.99
Evidence-based Routine Use in OA: Not Recommended by NICE â Confidence 0.98
đŠ PART 7 â BANGLADESH DRUG OPTIONS
Table 2: MedEx-Listed Examples for Knee Osteoarthritis and Related Conditions
āύāĻŋāĻā§āϰ āĻāώā§āϧāĻā§āϞ⧠āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ MedEx-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤāĨ¤ āĻāĻā§āϞ⧠āĻāĻāĻ āϰā§āĻā§ āϏāĻŦ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻĒāϝā§āĻā§āϤ āύ⧠āĻāĻŦāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ, āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžā§ā§ āύāĻŋāϤ⧠āĻšā§āĨ¤
| No. | Drug / Brand Examples | Generic / Class | Clinical Purpose | Important Note |
|---|---|---|---|---|
| 1 | Diclofenac topical formulations | Topical NSAID | Local knee pain relief â āĻšāĻžāĻāĻā§āϰ āϏā§āĻĨāĻžāύā§ā§ āĻŦā§āϝāĻĨāĻž āĻāĻŽāĻžāύ⧠| NICE first-line pharmacological option |
| 2 | Ternilla, Acebid | Aceclofenac | Pain and inflammation | GI, renal, cardiovascular risk |
| 3 | Other licensed NSAID brands | NSAID | Short-term symptom relief | Avoid unnecessary duplicate NSAIDs |
| 4 | Maxpro MUPS, Nexum MUPS | Esomeprazole | Oral NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ⧠Gastroprotection | OA-āĻāϰ āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻž āύ⧠|
| 5 | Ostocal DX, Ostogen D Forte | Calcium + Vitamin D | Deficiency āĻŦāĻž bone-health indication | Routine OA cure āύ⧠|
| 6 | Arthrosin TS, Arth-A TS | Glucosamine + Chondroitin | Joint supplements | NICE does not recommend glucosamine for OA |
MedEx Generic Directories
1. Aceclofenac alternatives:
MedEx Aceclofenac Brand List
2. Esomeprazole MUPS alternatives:
MedEx Esomeprazole MUPS Brand List
3. Calcium + Vitamin D alternatives:
MedEx Calcium and Vitamin D Brand List
4. Glucosamine + Chondroitin alternatives:
MedEx Glucosamine and Chondroitin Brand List
Evidence Confidence: 0.96 for MedEx classification; prescribing appropriateness must be assessed individually.
đ§ PART 8 â MANAGEMENT ACCORDING TO GUIDELINES
17. Management / Treatment â āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦā§āϝāĻŦāϏā§āĻĨāĻž
A. Conservative Management â āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž
1. Supervised Physiotherapy â āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āϤāϤā§āϤā§āĻŦāĻžāĻŦāϧāĻžāύ⧠āĻĢāĻŋāĻāĻŋāĻāĻĨā§āϰāĻžāĻĒāĻŋ
Quadriceps strengthening, controlled knee rehabilitation āĻāĻŦāĻ functional trainingāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āϰ āϏāĻžāĻŽāύā§āϰ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āĻāϰāĻž āĻāĻŦāĻ āĻšāĻžāĻāĻā§āϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻĒā§āύāϰā§āĻĻā§āϧāĻžāϰāĨ¤
2. Activity Modification â āĻāĻžāĻāĻāϰā§āĻŽā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
āĻšāĻžāĻāĻā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻāĻžāĻĒ āϏā§āώā§āĻāĻŋ āĻāϰ⧠āĻāĻŽāύ āĻāĻžāĻ āϏāĻžāĻŽā§āĻŋāĻāĻāĻžāĻŦā§ āϏā§āĻŽāĻŋāϤ āĻāϰāĻžāĨ¤
3. Weight Management â āĻāĻāύ āύāĻŋā§āύā§āϤā§āϰāĻŖ
āϰā§āĻā§ Overweight āĻšāϞ⧠āĻāĻāύ āĻāĻŽāĻžāύ⧠Knee OA-āĻāϰ āĻāĻĒāϏāϰā§āĻ āύāĻŋā§āύā§āϤā§āϰāĻŖā§ āϏāĻšāĻžā§āĻāĨ¤
4. Pain Management â āĻŦā§āϝāĻĨāĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻž
Knee OA-āϤ⧠āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠Topical NSAID guideline-supported āĻĒā§āϰāĻĨāĻŽ Pharmacological OptionāĨ¤
Oral NSAID āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āϏāĻŽā§ GI, Renal āĻāĻŦāĻ Cardiovascular Risk āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
5. Knee Bracing â āĻšāĻžāĻāĻā§āϰ āĻŦā§āϰā§āϏ
Documented Instability āĻĨāĻžāĻāϞ⧠āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļā§ Appropriate PCL Brace āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžā§āĨ¤
B. Surgical Evaluation â āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ
āύāĻŋāĻā§āϰ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠Knee Surgeon-āĻāϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§:
- Persistent symptomatic instabilityāĨ¤
- Significant PCL laxityāĨ¤
- Associated multiple-ligament injuryāĨ¤
- Persistent pain despite structured rehabilitationāĨ¤
- Severe function-limiting Post-Traumatic OAāĨ¤
Important: PCL injury āĻĨāĻžāĻāϞā§āĻ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰ āĻĒā§āϰā§ā§āĻāύ āĻšā§ āύāĻžāĨ¤ Injury severity, functional limitation āĻāĻŦāĻ associated injuries āĻ āύā§āϝāĻžā§ā§ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύāĻŋāϤ⧠āĻšā§āĨ¤
Management Confidence: 0.94
đŠ PART 9 â ADVICE
Clinical Advice â āϰā§āĻā§āϰ āĻāύā§āϝ āĻĒāϰāĻžāĻŽāϰā§āĻļ
1. Specialist Review: āĻĒā§āϰā§āύ⧠injury-āĻāϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻžāϰ āϏāĻā§āĻā§ āύāϤā§āύ āĻāĻĒāϏāϰā§āĻā§āϰ āĻŽāĻŋāϞ āĻāĻā§ āĻāĻŋ āύāĻž āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠Orthopedic Knee Specialist-āĻāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļāĨ¤
2. Imaging Review: āĻāĻā§āϰ āĻ āύāϤā§āύ MRI/X-ray āĻĨāĻžāĻāϞ⧠āϤā§āϞāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
3. Rehabilitation: Physiotherapist-āĻāϰ āϤāϤā§āϤā§āĻŦāĻžāĻŦāϧāĻžāύ⧠āĻĒāϰā§āϝāĻžā§āĻā§āϰāĻŽā§ Quadriceps StrengtheningāĨ¤
4. Medication Safety: āĻĒā§āϰā§āύ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĻā§āĻā§ Aceclofenac āĻāĻŦāĻžāϰ āύāĻŋāĻā§ āĻĨā§āĻā§ āĻļā§āϰ⧠āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
5. Avoid Duplicate NSAIDs: āĻāĻāĻžāϧāĻŋāĻ NSAID āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠āĻāĻāĻŋāϞāϤāĻžāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§ā§āĨ¤
6. Warning Signs: āύāϤā§āύ āĻāĻāĻžāϤā§āϰ āĻĒāϰ⧠āĻĒāĻž āĻ āĻžāύā§āĻĄāĻž āĻŦāĻž āĻ āĻŦāĻļ āĻšā§ā§ āϝāĻžāĻā§āĻž, āϤā§āĻŦā§āϰ āĻĢā§āϞāĻž, āĻšāĻžāĻāĻā§āϤ⧠āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϞāĻā§āώāĻŖ, āĻāĻŋāĻāĻŦāĻž āĻĒāĻžā§ā§ āĻāϰ āĻĻāĻŋāϤ⧠āύāĻž āĻĒāĻžāϰāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.96
đ§ PART 10 â CLINICAL PRESCRIPTION DEMONSTRATION
Educational Clinical Assessment & Prescription-Note Demo
DEMONSTRATION ONLY â NOT A VALID PRESCRIPTION OR MEDICATION ORDER
Department: Orthopedics & Trauma Surgery
Patient: Patient X
Age/Sex: Approximately 26 years / Male â historical document
Date of Review: 28 October 2026
C/C
Not documented in the historical prescription.
Possible symptoms to verify:
- Chronic knee pain.
- Subjective instability.
- Functional difficulty.
H/O
- Previous PCL injury â documented historically.
- Previous tibial plateau fracture â documented historically.
- Previous surgery and rehabilitation â unknown.
O/E
- Possible thigh muscle wasting.
- Possible positive posterior drawer test.
- ROM and neurovascular examination â not documented.
Investigations
- MRI of affected knee â historically requested.
- Knee radiographs â historically requested.
- Additional assessment based on current specialist examination.
Dx â Working Clinical Assessment
1. Old PCL Injury with Suspected Chronic PCL Insufficiency, Knee â Laterality to Confirm.
2. Suspected Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.
3. Possible Chronic Quadriceps Muscle Atrophy.
āĻŦāĻžāĻāϞāĻž Dx
ā§§. āĻšāĻžāĻāĻā§āϰ āĻĒā§āϰā§āύ⧠PCL āϞāĻŋāĻāĻžāĻŽā§āύā§āĻā§āϰ āĻāĻāĻžāϤ āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻžāĨ¤
⧍. āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠Tibial Plateau Fracture-āĻāϰ āĻĒāϰ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻāĻžāϤāĻāύāĻŋāϤ āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻāĻŋāĻāĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏāĨ¤
ā§Š. āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāĻžāĻāĻā§āϰ āϏāĻŽāϏā§āϝāĻžāϰ āĻāĻžāϰāĻŖā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Quadriceps Muscle AtrophyāĨ¤
Plan
- Confirm laterality and current symptoms.
- Review MRI and radiographs.
- Assess PCL stability and functional impairment.
- Begin or continue appropriate supervised rehabilitation after assessment.
- Review analgesic need and NSAID risks.
- Refer to Orthopedic Knee / Sports Injury Specialist.
Medication Documentation
Historical prescription contained:
Ternilla 100 mg, Maxpro MUPS 20 mg, Ostocal DX and Arthrosin TS.
Exact historical administration schedule and duration require verification from the original prescription or treating physician.
No new patient-specific medication order is issued in this demonstration.
Clinical Note Confidence: 0.84 for the provisional assessment.
đŠ PART 11 â APPROPRIATE REFERRAL
Which Doctor Should Manage This Patient?
Primary Referral
Orthopedic Surgeon â Knee Ligament & Sports Injury Specialist
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āϞāĻŋāĻāĻžāĻŽā§āύā§āĻ āĻ āĻĒā§āϰā§āύ⧠āĻāĻāĻžāϤā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻ āĻāĻŋāĻā§āĻ āĻ āϰā§āĻĨā§āĻĒā§āĻĄāĻŋāĻ āϏāĻžāϰā§āĻāύāĨ¤
Secondary Referral
Physical Medicine & Rehabilitation Specialist
āĻŦāĻžāĻāϞāĻž: āĻĒā§āύāϰā§āĻŦāĻžāϏāύ āĻ āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāύā§āύā§āύā§āϰ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Physiotherapy
Musculoskeletal Physiotherapist
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāĻāĻā§āϰ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž, āĻŽāĻžāĻāϏāĻĒā§āĻļāĻŋāϰ āĻļāĻā§āϤāĻŋ āĻ āĻĻā§āύāύā§āĻĻāĻŋāύ āĻāϞāĻžāĻĢā§āϰāĻžāϰ āϏāĻā§āώāĻŽāϤāĻž āĻāύā§āύā§āύā§āϰ āĻāύā§āϝāĨ¤
Referral Confidence: 0.97
đ§ PART 12 â OVERVIEW / SUMMARY
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ āĻŦā§āĻāĻž āϝāĻžāĻā§āĻā§, āĻāĻŋāĻāĻŋā§āϏāĻ āĻāĻāĻāĻŋ āĻĒā§āϰā§āύ⧠āĻšāĻžāĻāĻā§āϰ āĻāĻāĻžāϤ, PCL Injury, Tibial Plateau Fracture āĻāĻŦāĻ Knee Osteoarthritis-āĻāϰ āϏāĻŽāϏā§āϝāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰā§āĻāĻŋāϞā§āύāĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ Positive Posterior Drawer Test āĻ Thigh Muscle Wasting PCL-related chronic functional impairment-āĻāϰ āĻĒāĻā§āώ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Clinical ClueāĨ¤
āϤāĻŦā§ Imaging Results āύāĻž āĻĨāĻžāĻāĻžā§ PCL Tear-āĻāϰ Grade, Osteoarthritis-āĻāϰ Severity āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻšāĻžāĻāĻā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤
Final Clinical Impression
Suspected Chronic PCL Insufficiency with Post-Traumatic Knee Osteoarthritis Following Previous Tibial Plateau Fracture.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āύ⧠PCL āĻāĻāĻžāϤāĻāύāĻŋāϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻšāĻžāĻāĻā§āϰ āĻ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāĻŋāĻŦāĻŋā§āĻžāϞ āĻĒā§āϞā§āϝāĻžāĻā§ āĻĢā§āϰā§āϝāĻžāĻāĻāĻžāϰā§āϰ āĻĒāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ āϏā§āĻāĻŋāĻāĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏāĨ¤
Diagnostic Confidence: 0.76 â Provisional.
đŠ PART 13 â ACTIONABLE CLINICAL PLAN
Step 1: Identify the correct affected knee â āĻĄāĻžāύ āύāĻž āĻŦāĻžāĻŽ āĻšāĻžāĻāĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāĨ¤
Step 2: Obtain original injury, treatment and operative history â āĻĒā§āϰā§āύ⧠āĻāĻāĻžāϤ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āϏāĻāĻā§āϰāĻšāĨ¤
Step 3: Perform detailed knee examination â āĻšāĻžāĻāĻā§āϰ āĻĒā§āϰā§āĻŖāĻžāĻā§āĻ āĻĒāϰā§āĻā§āώāĻžāĨ¤
Step 4: Review MRI and X-ray findings â āĻĒā§āϰā§ā§āĻāύā§ā§ Imaging āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Step 5: Assess functional instability and OA severity â āĻšāĻžāĻāĻā§āϰ āϏā§āĻĨāĻŋāϤāĻŋāĻļā§āϞāϤāĻž āĻ āĻā§āώā§ā§āϰ āĻŽāĻžāϤā§āϰāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖāĨ¤
Step 6: Establish a tailored rehabilitation and pain-management plan â āϰā§āĻā§āĻā§āĻĻā§ āĻĒā§āύāϰā§āĻŦāĻžāϏāύ āĻ āĻŦā§āϝāĻĨāĻž āύāĻŋā§āύā§āϤā§āϰāĻŖāĨ¤
Step 7: Refer for surgical assessment only when indicated â āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠āϏāĻžāϰā§āĻāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Plan Confidence: 0.95
đ PART 14 â REFERENCE LIST
A. Medical Textbooks
1. Campbell’s Operative Orthopaedics.
14th Edition. Elsevier.
Relevant sections: Knee ligament injuries and post-traumatic joint disorders.
2. Bailey & Love’s Short Practice of Surgery.
27th Edition.
Relevant sections: Orthopaedic trauma, fracture management and joint disorders.
3. Harrison’s Principles of Internal Medicine.
21st Edition. McGraw Hill.
Relevant section: Osteoarthritis.
Textbook page numbers are intentionally omitted because exact pagination has not been independently verified.
B. International Clinical Guidelines
4. NICE Guideline NG226 (2022).
Osteoarthritis in over 16s: Diagnosis and Management.
NICE NG226 Official Recommendations
5. American College of Rheumatology/Arthritis Foundation (2019 Guideline; published 2020).
Management of Osteoarthritis of the Hand, Hip, and Knee.
DOI: 10.1002/acr.24131
C. Peer-Reviewed Journals â Verified DOI
6. Verhulst FV, MacDonald P. (2020).
Diagnosing PCL Injuries: History, Physical Examination, Imaging Studies, Arthroscopic Evaluation.
Sports Medicine and Arthroscopy Review.
DOI: 10.1097/JSA.0000000000000251
7. Cook CR, Wissman RD. (2021).
Imaging Review of the Posterior Cruciate Ligament.
Journal of Knee Surgery.
8. Aurich M, Koenig V, Hofmann G. (2018).
Comminuted Intraarticular Fractures of the Tibial Plateau Lead to Posttraumatic Osteoarthritis of the Knee.
Asian Journal of Surgery.
DOI: 10.1016/j.asjsur.2016.11.011
9. Kolasinski SL, et al. (2020).
2019 American College of Rheumatology/Arthritis Foundation Guideline for Management of Osteoarthritis.
Arthritis & Rheumatology.
DOI: 10.1002/art.41142
10. Wilebski BJ, et al. (2026).
Current Standards for Objective Assessment and Management of Posterior Cruciate Ligament Tears: A Narrative Review.
Annals of Joint.
DOI: 10.21037/aoj-25-52
D. Bangladesh Drug Information
11. MedEx Bangladesh.
Verified brand monographs:
- Ternilla 100 mg.
- Maxpro MUPS 20 mg.
- Ostocal DX.
- Arthrosin TS.
FINAL PUBLICATION DECLARATION
This article represents a retrospective interpretation of an uploaded historical prescription. It does not establish the patient’s current diagnosis, reproduce an independently verified examination or substitute for specialist evaluation.
Confidence values are qualitative assessments of evidence and transcription certainty, not statistically validated diagnostic probabilities.
Author Name: Md.Rafiqul Islam Lipu
Publication: LIPU MED â Clinical Prescription Review
Website: raiyyantahsan.com
Department: Orthopedics & Trauma Surgery
Date: Wednesday, 28 October 2026
Time: 02:11 PM (Bangladesh Standard Time, UTC+06:00)
Status: Educational Clinical Case Review â Provisional Diagnosis